Wednesday, July 8, 2026

Patent intelligence · US

US 9370510

Small molecule compounds to treat hearing loss

granted A61KA61K31/404A61K31/475A61K31/506
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 10
Applicant portfolio 53
Patent details — US 9370510
Jurisdiction
US
Status
granted
Grant date
Jun 21, 2016
Expiration
Jun 16, 2036
Claims
22
CPC classes
A61K, A61K31/404, A61K31/475, A61K31/506
View on Google Patents ↗

Quick answer

US 9370510 (Small molecule compounds to treat hearing loss) is held by Fate Therapeutics, Inc.. Status: granted. Granted Jun 21, 2016. Expires Jun 16, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
22
CPC classes
A61K, A61K31/404, A61K31/475, A61K31/506, A61K31/55, A61K9/0046

More from Fate Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Apr 17, 2045

    granted
  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Expires Apr 10, 2045

    granted
  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Expires Mar 27, 2045

    granted
  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Expires Mar 6, 2045

    granted

Frequently asked questions

What is US patent 9370510?

US 9370510 (Small molecule compounds to treat hearing loss) is held by Fate Therapeutics, Inc.. Status: granted. Granted Jun 21, 2016. Expires Jun 16, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9370510?

Fate Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.

When does US 9370510 expire?

Our index shows an expiration date of Jun 16, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.